Application of AMR in evaluating microvascular dysfunction after ST-segment elevation myocardial infarction

1. Introduction

Coronary microvascular dysfunction (CMD) plays an important role in myocardial ischemia in many cardiovascular diseases, and coronary artery disease (CAD) is a common cardiovascular condition in which CMD can contribute to its formation and progression [1,2]. Notably, post-reperfusion CMD is not uncommon in ST-segment elevation myocardial infarction (STEMI) patients, and the occurrence of microvascular obstruction (MVO) is also associated with poor clinical prognosis [3].

The index of microcirculatory resistance (IMR) is a quantitative and repeatable method for evaluating CMD based on intracoronary guidewire [4], but the clinical application of IMR is still limited by dilating drugs, pressure guidewires, long measurement times, and high costs. Functional assessment is becoming increasingly important in patients with coronary artery disease, and quantitative flow ratio (QFR) is an emerging angiography-based assessment method that facilitates the calculation of fractional flow reserve (FFR) values by three-dimensional (3D) coronary reconstruction and fluid dynamics [5]. The accuracy of QFR has been confirmed by many large RCT studies, including the FAVOR Pilot study, the FAVOR II study, and the FAVOR III study, which further validated the diagnostic value of QFR and the accuracy of assessing coronary ischemia [5–10]. In addition, QFR eliminates the need for pressure guidewires and is a suitable option for assessing coronary ischemia [6]. And a guidewire-free and adenosine-free angiography-derived microcirculatory resistance (AMR) derived from QFR with flow velocity calculation has good diagnostic accuracy in the assessment of CMD, providing an effective clinical alternative to invasive pressure guidewire-based IMR [11].

Although QFR is an important tool for functional assessment in patients with CAD, the specific application and assessment value of AMR in STEMI patients still lacks support from relevant studies. Therefore, our study aimed to explore the value of AMR in assessing the incidence of major adverse cardiac events (MACE) by evaluating postoperative AMR and follow-up characteristics in STEMI patients.

2. Materials and Methods

3. RESULTS

3.1 Baseline characteristics

As shown in Figure 1, this study included a total of 514 patients with AMI, 3 patients refused PCI procedures, and 5 patients had poor quality QFR images, resulting in the inclusion of 506 STEMI patients divided into the CMD group (AMR ≥250 mmHg*s/m, n=215) and the Non-CMD group (AMR <250 mmHg*s/m, n=291). The clinical, laboratory, and angiographic characteristics of each group are shown in Table 1. The mean age was 63 years, 416 males (82.2%), 90 females (17.8%), 137 (27.1%) had diabetes mellitus, 265 (52.4%) had hypertension, and 138 (27.3%) had hyperlipidemia. There was no significant difference between the CMD group and the non-CMD group in the incidence of hypertension, diabetes mellitus, previous smoking, family history of coronary heart disease, previous stroke, previous myocardial infarction, used antiplatelet drug, used statin, and LVEF (P > 0.05). Compared with non-CMD patients, CMD patients were significantly older [67.00 (56.00-74.00) vs. 60.00 (51.75-72.00) years, P=0.000], less proportionally male [167 (77.7%) vs. 249 (85.6%), P=0.022], had a lower body mass index [22.64 (20.28-23.66) vs. 22.64 (20.28-25.35) kg/m2, P=0.017], a lower proportion of hyperlipidemia [47 (21.9%) vs. 91 (31.3%), P=0.019], and less use of ACEI/ARB medications [120 (55.8%) vs. 192 (66%), P= 0.020]. Among biochemical indicators, compared with non-CMD patients, CMD patients had lower serum albumin [37.99±3.97 vs. 39.01±3.90 g/L, P=0.004], higher neutrophils [8.09 (5.79-10.46) vs. 7.16 (5.45-9.68)*10^9/L, P=0.034], and lower lymphocytes [1.41 (0.95-1.94) vs. 1.59 (1.04-2.37)*10^9/L, P=0.024], higher BNP [189.19 (78.09-485.36) vs. 142.55 (50-401.82) pg/ml, P=0.011], lower LDL-c [2.67 (2.14-3.31) vs. 2.85 (2.36-3.44) mmol/L, P=0.022]; There was no significant difference in other indexes between the two groups (P > 0.05).

• Download figure
• Open in new tab

Figure 1:

Study flowchart diagram.

• Download figure
• Open in new tab

Figure 2:

An example of Quantitative flow ratio (QFR) and Coronary microvascular dysfunction (CMD) analysis. (a) diagnostic angiographic projections show Right coronary artery (RCA) with residual stenosis; (b) QFR and AMR after PCI were calculated. QFR is 0.96, AMR is 307mmHg*s/m, flow speed is 1l.8cm/s.

View this table:

• View inline
• View popup

Table 1:

Baseline characteristics

Using the propensity score matching method (PSM) with a caliper value of 0.02, a total of 191 pairs were successfully matched between the two groups. Covariates that were not balanced between the two groups were balanced after matching (P > 0.05, Table 1).

3.4 One-Year Follow-Up Characteristics

The clinical characteristics of the two groups at 1 year of follow-up were shown in Table 4. At 1-year follow-up, the primary endpoint occurred in a total of 48 cases (9.5%), of which 30 and 18 cases were from the CMD and Non-CMD groups (HR 2.326 [95% CI 1.297 to 4.172]; 14.0% vs. 6.2%, P=0.005); a total of 22 cases (4.3%) were readmitted for heart failure in the subgroup analysis, of which 16 and 6 cases were from the CMD and Non-CMD groups (HR 3.741 [95% CI 1.464 to 9.562]; 7.4% vs. 2.1%, P=0.006).

View this table:

• View inline
• View popup
• Download powerpoint

Table 4:

1-year clinical outcomes

Analyses were performed in the intention-to-treat population. Kaplan-Meier curves show the cumulative incidence of MACE, and HF readmission (Figure 3 and Figure 4); while a total of 24 cases (4.8%) had all-cause death, 2 cases (0.4%) had a myocardial infarction, and 0 cases (0%) had target vessel revascularization, and there was no statistical difference between the two groups (P> 0.05). A total of 11 (2.2%) cases of cardiac-related death and 13 (2.6%) cases of non-cardiac-related death occurred in the secondary endpoint, and there was no statistical difference between the two groups for both cardiac-related and non-cardiac-related deaths (P > 0.05).

• Download figure
• Open in new tab

Figure 3:

Kaplan-Meier curves for the primary endpoints in the intention-to-treat population

• Download figure
• Open in new tab

Figure 4:

Kaplan-Meier curves for heart failure in the intention-to-treat population

After PSM, at 1-year follow-up, the primary endpoint occurred in a total of 41 cases (10.7%), of which 27 and 14 were from the CMD and Non-CMD groups (HR 1.954 [95% CI 1.025 to 3.726]; 14.1% vs. 7.3%, P=0.042); a total of 18 cases (4.7%) were readmitted for heart failure in the subgroup analysis. Of these, 15 and 3 were from the CMD and Non-CMD groups (HR 5.082 [95% CI 1.471 to 17.554]; 7.9% vs. 1.6%, P=0.010); while a total of 21 (5.5%) had all-cause death, 2 (0.4%) had myocardial infarction, and 0 (0%) had target vessel revascularization, and there was no statistical difference between the two groups (P > 0.05). A total of 8 (2.1%) cases of cardiac-related death and 13 (3.4%) cases of non-cardiac-related death occurred in the secondary endpoint, and there was no statistical difference between the two groups for both cardiac-related and non-cardiac-related deaths (P > 0.05). Contributing to the main composite outcome was the higher incidence of HF readmission by the CMD group compared to the non-CMD group.

Univariate and multifactor predictors of the primary endpoint are listed in Table 5. The 14 independent variables of significance: post-PCI AMR ≥250 mmHg*s/m, age, sex, BMI, diabetes, hypertension, hyperlipidemia, stroke, HBA1c, BNP, Albumin, Peak value of cTnI, random blood glucose, and LVEF were included in the multifactorial COX regression analysis using a univariate COX regression model. Post-PCI AMR ≥250 mmHg*s/m was obtained to be significantly associated with a higher risk of the primary endpoint and was its independent predictor (pre-matched adjusted HR 2.037, 95% CI: 1.068 to 3.888, P = 0.031; post-matched adjusted HR 2.265, 95% CI: 1.136 to 4.515, P = 0.020), as well as age, BNP and Peak value of cTnI (Table 5).

View this table:

• View inline
• View popup
• Download powerpoint

Table 5:

Univariate and multivariate analysis results for predictors of 1-year MACE

4. Discussion

In this study, we evaluated CMD in STEMI patients by AMR index, thus exploring the predictive value of AMR on the occurrence of adverse events in STEMI patients. The main findings of this study are as follows:1. Regarding clinical outcomes, we found a higher incidence of MACE in the CMD group, which was mainly due to a higher incidence of heart failure readmission.2. Multivariate COX regression analysis showed that AMR≥250mmHg*s/m, age, peak troponin I and BNP were independent risk factors for 1-year MACE occurrence.

Current diagnostic methods for evaluating CMD include non-invasive tests such as positron emission tomography (PET), cardiac echocardiography, cardiac CT scan, and cardiac magnetic resonance (CMR), as well as invasive tests such as coronary angiography, Doppler flow map, coronary flow reserve (CFR), and IMR. PET is now considered the gold standard reference for non-invasive evaluation of CMD, but its high cost, inability to measure repeatedly, and radiological damage have limited its use in clinical practice [15]; The main limitation of CMR is the adverse reactions caused by gadolinium contrast agent in patients with renal insufficiency. Previously, invasive IMR has been studied more frequently, and research evidence suggests that IMR can accurately assess patients’ CMD [16], and it is now mostly considered that coronary microcirculatory dysfunction is present at IMR ≥ 25 [17]. In previous work, Fearon et al. [18] reported that high IMR > 40 measured at initial PCI in STEMI patients predicted long-term clinical outcomes, such as a death in HF and rehospitalization. IMR of the Culprit vessel measured immediately after successful initial PCI in STEMI patients can assess the prognosis of the patient. However, additional requirements for pressure-temperature transducer wires and insufflators limit their use in routine procedures.

With the increasing variety of functional evaluation, we are no longer limited to the use of assessment tools such as IMR calculated by pressure and temperature lines; Tebaldi M et al. [19] validated for the first time the formula for calculating microvascular resistance based on cQFR data without the use of pressure guidewires and drug-induced congestion. In contrast, a study by Sheng X et al. [20] found that QFR calculation may be a useful tool for predicting CMD after STEMI; as studies have progressed, more and more studies have shown that it is feasible to assess coronary microcirculatory resistance in the absence of intracoronary pressure guidewires and congestive drugs [21]. Studies published during the same period have shown that the non-hyperaemic angiography-derived index of microcirculatory resistance (NH-IMRangio) is prognostically equivalent to invasively measured IMR and may be a viable alternative to IMR in patients with STEMI [22]. In recent studies, the AMR index obtained from a single angiographic view only is a feasible computational alternative to pressure-guided IMR with good diagnostic accuracy in the assessment of CMD [11]. In patients with AMI, current noninvasive examinations and invasive IMR to assess microcirculatory function are less than perfect, which also poses a challenge for early and accurate functional assessment in AMI patients. Undeniably, with the development of functional coronary angiography, we can find AMR to be a good solution to this problem. In STEMI patients, AMR offers a safe and effective, reproducible, and rapidly calculated alternative to guidewire-based IMR measurements.

The prognostic impact of the occurrence of CMD is important for STEMI patients, and previous studies have shown that STEMI patients with Angio-IMR > 40 U have a significantly higher risk of cardiac death or heart failure admission than controls [23], while in a study by Scarsini et al. [16] it was observed that STEMI patients admitted by invasive IMR > 40 U or CMD assessed by CMR showed adverse outcomes mainly caused by the development of heart failure; it is undeniable that PCI significantly reduces in-hospital mortality in STEMI patients, but the incidence of HF after STEMI is not uncommon in clinical practice, which may be that post-ischemic CMD plays an important role and is also consistent with the higher incidence of heart failure readmission in patients in the CMD group in this study results are consistent with this.

CMD is an important pathological change in STEMI patients after reperfusion therapy and is often associated with poor prognosis [24]. Rapid and accurate assessment of CMD in the acute phase of STEMI appears to be important. In a recent study, Yongzhen Fan et al. [11] found that AMR, as a QFR-derived calculated index, had a good correlation (r = 0.83, p < 0.001) and diagnostic performance (AUC 0.94; 95% CI: 0.91 to 0.97) with an optimal threshold value of 250 mmHg *s/m for AMR when IMR ≥ 25. In this study, a subgroup analysis was performed based on this cutoff value, and although there was statistical significance in age, sex ratio, and past medical history between the two groups for the baseline data, the difference between the two baseline data was improved by PSM and made the two groups more comparable, and 14 independent variables that were clinically relevant or significant were included in the multifactor COX regression analysis by univariate COX regression analysis, and the results Post-PCI AMR ≥250 mmHg*s/m after matching was found to be significantly associated with a higher risk of the primary endpoint and was an independent predictor of it.

STEMI is a common acute and critical clinical condition caused by acute myocardial ischemia, prevalent in the elderly population, with rapid progression, and is one of the serious threats to the physical health of the elderly. In our study, baseline data showed that patients with CMD were significantly older compared to patients with the non-CMD [67.00 (56.00-74.00) vs. 60.00 (51.75-72.00) years, P=0.000]; after incorporating multifactorial COX regression analysis, it was concluded that age in STEMI patients was associated with a higher risk of the primary endpoint association (adjusted HR 1.045, 95% CI: 1.015-1.076, P = 0.003).

BNP is a counter-regulatory peptide hormone synthesized mainly in the ventricular myocardium. As a highly sensitive and specific biomarker of the degree of myocardial infarction, in non-ST-segment elevation ACS patients, patients with high BNP at presentation are at higher risk of death and congestive heart failure[25]and is an independent predictor of very long-term all-cause mortality [26]. Elevated BNP concentrations at initial presentation in STEMI patients are associated with a higher risk of death in the short term [27] [28]. And in our study, we also came to the consistent conclusion that BNP was higher in CMD patients compared to the non-CMD patients [189.19 (78.09-485.36) vs. 142.55 (50-401.82) pg/ml, P=0.011], and after including a multifactorial COX regression analysis, it was concluded that high BNP at admission in STEMI patients was associated with a major higher risk at the endpoint (adjusted HR 1.000, 95% CI: 1.000-1.000, P = 0.019).

In patients with NSTE-ACS treated with PCI, higher peak pre-procedure cTnI levels were independently associated with 30-day mortality and composite MACE [29]. By 3-month follow-up, troponin I was associated with clinical outcomes and cardiac function in STEMI patients treated with initial PCI [30]. Whereas in our findings, neither troponin I nor peak troponin I were statistically different in CMD patients admitted to the hospital compared to the non-CMD patients (P > 0.05), after inclusion of multifactorial COX regression analysis, it was concluded that peak troponin I in STEMI patients was associated with a higher risk of the primary endpoint (adjusted HR 1.022, 95% CI: 1.004 -1.041, P= 0.019).

Diabetes mellitus is a metabolic disease with macrovascular and microvascular complications. Since endothelial dysfunction plays an important role in the cardiovascular complications of diabetes, an association between previous history of diabetes, hyperglycemia, and post-ischemic CMD seems reasonable. A prospective trial of non-diabetic patients presenting for the first time with STEMI confirmed that hyperglycemia on admission was significantly associated with MVO as defined by CMR [31]. In contrast, in our study, history of diabetes, glucose level at admission, and HbA1c were not statistically significant between the CMD and Non-CMD groups, nor was the inclusion of HbA1c in the multifactorial COX regression analysis between groups (adjusted HR 0.932, 95% CI: 0.587 to 1.480, P= 0.766); this may be related to our lower prevalence of diabetes mellitus in the included population and the smaller sample size.

Recent advances in functional coronary angiography have made it possible to estimate physiologic indicators based on coronary angiography alone, without the use of pressure-temperature sensor wires or congestive drugs. In the present study, we evaluated the prediction of adverse events by AMR in patients with STEMI. In STEMI patients, early assessment of AMR is convenient and allows earlier administration of medications for microcirculatory disorders. QFR and AMR may be more readily adopted into the workflow of angiography-based diagnostic and interventional procedures than invasive physiologic assessments, do not require the use of specialized guidewires, and can be easily repeated multiple times during the procedure. It may thus facilitate the routine use of physiological assessment in clinical practice.CMD is prevalent in patients with cardiovascular risk factors and is associated with an increased risk of adverse events and is an important cause of coronary artery disease (CAD) [2]. Some investigators have suggested that oxidative stress and inflammatory responses caused by excessive production and accumulation of cellular reactive oxygen species (ROS) are the key mechanisms driving the development of CMD [32]. In vitro and in vivo studies have shown that increased intracellular ROS concentrations promote the conversion of NO in peroxynitrite radicals, leading to impaired NO-mediated vasodilation and enhanced vasoconstrictor activity of ET-1 (vasoconstrictor agonist) through activation of the RhoA/Rho-kinase pathway [33] [34]. In patients with STEMI, there is no effective treatment to improve MVO [35]; no large-scale randomized clinical trials have been seen to study specific treatment strategies for CMD, the pathophysiological mechanisms of CMD in different cardiovascular diseases have not been fully elucidated, and there is a lack of treatment options for CMD, which require further in-depth studies to achieve the goal of providing individualized treatment for patients [2]. Therefore, active control of risk factors including smoking cessation, rational control of blood pressure and diabetes, lipid management, and treatment of the primary disease are effective means to prevent the progression of microangiopathy and improve angina symptoms. In addition, early identification of high-risk patients is crucial as early development of individualized treatment strategies to improve long-term prognosis.

The present study still has some limitations. First, this is a retrospective single-center observational study with a small sample size, and further prospective multicenter cohort studies are needed to validate the findings. Second, not all images are suitable for QFR and AMR analysis, which may lead to selection bias. Third, individual vessel AMR immediately after primary PCI may not fully explain the overall prognosis of patients, and the focus of this study was limited to the analysis of microcirculatory dysfunction in the vascular region of the culprit in STEMI patients. Therefore, studies such as comparative prognosis of UA, NSTEMI patients, and non-culprit vascular regions with potential microcirculatory dysfunction may be the next research plan of our group. Fourth, the MACE in this study was a 1-year follow-up, which is a short period, and the follow-up will continue for a longer period. In addition, since most of the follow-ups were conducted by telephone and returned to the hospital, which was affected by economic conditions and epidemics, it is a pity that there is no data on coronary reexamination 1 year after myocardial infarction.

5. Conclusion

With the development of techniques and devices, AMR as a guidewire-free and adenosine-free index for the assessment of coronary microcirculatory impairment may become a viable alternative to invasive guidewire-based IMR in patients with STEMI.

6. Sources of Funding

None.

7. Disclosures

None.